sub:assertion {
<
http://purl.obolibrary.org/obo/MONDO_0008114>
a bl:Disease .
sub:association rdf:object <
http://purl.obolibrary.org/obo/MONDO_0008114> ;
rdf:predicate bl:treats ;
rdf:subject <
https://identifiers.org/DRUGBANK:DB01175> ;
a rdf:Statement ;
rdfs:label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." ;
bl:has_population_context sub:context ;
bl:provided_by <
https://w3id.org/um/NeuroDKG> ;
bl:publications <
https://pubmed.ncbi.nlm.nih.gov/30101713> ;
bl:relation nkg:OffLabelIndication .
sub:context a bl:Cohort ;
rdfs:label "adults" .
<
https://identifiers.org/DRUGBANK:DB01175>
a bl:Drug .
}